992
Participants
Start Date
March 31, 2025
Primary Completion Date
August 31, 2026
Study Completion Date
December 31, 2026
Phase IIb：Efsubaglutide Alfa 5 mg QW
IIb：Efsubaglutide Alfa 5 mg QW
Phase IIb：Efsubaglutide Alfa 10 mg QW
Efsubaglutide Alfa 10 mg QW
Phase IIb：Efsubaglutide Alfa 20 mg QW
Efsubaglutide Alfa 20 mg QW
Phase IIb：Efsubaglutide Alfa 20 mg Q2W
Efsubaglutide Alfa 20 mg Q2W
Phase IIb：Placebo
Placebo
Phase III：Recommended Phase 3 Dose High Dose
The Recommended Phase 3 Dose High Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
Phase III：Recommended Phase 3 Dose Low Dose
The Recommended Phase 3 Dose Low Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
Phase III：Placebo
Placebo
RECRUITING
Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai
RECRUITING
Beijing Tsinghua Changgung Hospital, Beijing
RECRUITING
Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital, Chengdu
RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhusi
RECRUITING
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
RECRUITING
The First People's Hospital of Yunnan Province, Kunming
RECRUITING
The Second Hospital of Nanjing Medical University, Nanjing
RECRUITING
The Affiliated Qingyuan Hospital ,Guangzhou Medical University（Qingyuan People's Hospital）, Qingyuan
RECRUITING
The First Hospital of Qinhuangdao, Qinhuangdao
RECRUITING
Shanghai General Hospital, Shanghai
RECRUITING
Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin
RECRUITING
Yueyang Central Hospital, Yueyang
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
OTHER